NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic
Urged by Prostate Cancer UK, NHS England is making Xtandi (enzalutamide) and Zytiga (abiraterone acetate) available during the COVID-19 pandemic for men with newly diagnosed advanced prostate cancer. Access to chemotherapy for these new patients has been stopped in the U.K. due to the nationwide lockdown. “We are delighted that NHS England have taken the landmark decision to make these drugs available and that men across the UK can now benefit from these life-extending treatments,” Heather Blake, director of support & influencing at Prostate Cancer UK, said in a
Subscribe or to access all post and page content.